Medicamen Organics Ltd

Medicamen Organ. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Medicamen Organics Ltd

₹ 22.9 1.55%
19 Jun - close price
medicamenorganics.com NSE - SME: MEDIORG
About

Incorporated in 1995, Medicamen Organics Ltd develops, manufactures, and distributes a broad range of pharmaceutical dosages including generic dosage[1]

Key Points

Business Overview:[1][2]
MOL specializes in manufacturing and distributing tablets, capsules, syrups, and ointments. It offers B2B contract and third-party manufacturing services for pharma companies in India and globally. Its portfolio includes generic and branded formulations, catering to government sectors, private institutions, and prominent pharma firms. Products are marketed via third-party distributors and loan licensing agreements.

Website NSE - SM
  • Market Cap ₹ 27.9 Cr.
  • Current Price ₹ 22.9
  • High / Low ₹ 48.8 / 19.1
  • Stock P/E
  • Book Value ₹ 23.7
  • Dividend Yield 0.00 %
  • ROCE -8.54 %
  • ROE -10.4 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Stock is trading at 0.97 times its book value

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -2.88% over past five years.
  • Company has a low return on equity of 3.48% over last 3 years.
  • Company might be capitalizing the interest cost
  • Company has high debtors of 303 days.
  • Working capital days have increased from 152 days to 245 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of Nifty SME Emerge

Edit Columns
Loading peers table ...

Half Yearly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2023 Mar 2024 Sep 2024 Mar 2025 Sep 2025 Mar 2026
11.32 13.95 16.61 20.48 17.05 4.60
8.91 11.62 14.09 17.67 13.78 10.67
Operating Profit 2.41 2.33 2.52 2.81 3.27 -6.07
OPM % 21.29% 16.70% 15.17% 13.72% 19.18% -131.96%
1.05 0.01 0.25 0.05 0.06 0.02
Interest 0.29 0.36 0.22 0.29 0.33 0.37
Depreciation 0.36 0.36 0.36 0.37 0.41 0.48
Profit before tax 2.81 1.62 2.19 2.20 2.59 -6.90
Tax % 51.96% 22.84% 30.59% 20.00% 25.10% -27.68%
1.36 1.26 1.51 1.76 1.94 -4.98
EPS in Rs 1.70 1.47 1.29 1.50 1.66 -4.09
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
31.49 25.05 20.98 22.15 25.27 37.09 21.65
30.14 23.41 19.78 20.29 20.53 31.53 24.43
Operating Profit 1.35 1.64 1.20 1.86 4.74 5.56 -2.78
OPM % 4.29% 6.55% 5.72% 8.40% 18.76% 14.99% -12.84%
0.09 0.01 0.21 0.82 1.07 0.10 0.07
Interest 0.46 0.48 0.47 0.61 0.65 0.54 0.71
Depreciation 0.77 0.68 0.68 0.71 0.72 0.74 0.89
Profit before tax 0.21 0.49 0.26 1.36 4.44 4.38 -4.31
Tax % 47.62% 40.82% 61.54% 28.68% 40.77% 25.34% -29.23%
0.10 0.30 0.09 0.97 2.62 3.27 -3.05
EPS in Rs 0.17 0.50 0.15 1.62 3.05 2.79 -2.51
Dividend Payout % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Compounded Sales Growth
10 Years: %
5 Years: -3%
3 Years: -1%
TTM: -42%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -193%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -52%
Return on Equity
10 Years: %
5 Years: 4%
3 Years: 3%
Last Year: -10%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 6.00 6.00 6.00 6.00 8.60 11.70 12.17
Reserves 1.11 1.47 1.56 2.98 6.66 18.02 16.64
8.27 9.59 10.24 11.79 12.66 12.13 13.69
10.44 9.28 9.27 11.82 10.52 15.60 7.99
Total Liabilities 25.82 26.34 27.07 32.59 38.44 57.45 50.49
11.28 11.35 11.29 10.87 10.35 10.13 13.28
CWIP 0.06 0.00 0.00 0.00 0.15 2.22 0.09
Investments 0.00 0.00 0.00 0.00 0.00 0.27 0.27
14.48 14.99 15.78 21.72 27.94 44.83 36.85
Total Assets 25.82 26.34 27.07 32.59 38.44 57.45 50.49

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1.58 -1.16 0.04 -0.58 -3.66 -4.91 -4.15
-0.45 -0.02 -0.59 -0.28 -0.34 -2.62 -1.63
-0.55 1.27 0.18 0.94 4.01 10.25 3.10
Net Cash Flow 0.58 0.09 -0.37 0.07 0.01 2.72 -2.67
Free Cash Flow 1.11 -1.19 -0.58 -0.87 -4.01 -7.36 -5.80
CFO/OP 117% -68% 9% -28% -73% -87% 145%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 63.98 109.72 108.73 177.47 241.21 243.56 302.96
Inventory Days 101.47 61.22 128.47 225.01 244.39 228.39 246.36
Days Payable 225.45 161.56 198.97 329.82 281.81 355.85 129.40
Cash Conversion Cycle -60.01 9.38 38.24 72.66 203.80 116.10 419.92
Working Capital Days -51.00 -47.06 -45.41 -25.71 74.24 137.77 245.47
ROCE % 5.98% 4.19% 10.22% 16.59% 14.10% -8.54%

Insights

In beta
Mar 2022 Mar 2023 Mar 2024 Mar 2025
Tablets Sales Contribution
%

Log in to view insights

Please log in to see hidden values.

Login
Installed Capacity - Capsules
Lakh capsules per annum
Installed Capacity - Dry Powder Sachets
Units per annum
Installed Capacity - Ointment
Kg per annum
Installed Capacity - Suspension/Oral Liquids
Liters per annum
Installed Capacity - Tablets
Lakh tablets per annum
Geographic Presence (Countries)
Number
Capacity Utilization (Average)
%
Order Book - Povidone Iodine Solution
Units
Total Product SKUs
Number

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

5 Recently
Sep 2024Mar 2025Sep 2025Mar 2026Jun 2026
59.69% 59.73% 59.73% 59.73% 54.89%
0.14% 0.07% 0.07% 0.07% 0.05%
3.76% 3.79% 3.69% 1.64% 0.00%
36.41% 36.41% 36.51% 38.56% 45.05%
No. of Shareholders 379460507540508

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls